12:00 AM
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

OGX-427: Phase II started

OncoGenex began the open-label, North American Phase II PACIFIC trial to compare IV OGX-427 plus once-daily oral Zytiga abiraterone acetate and once-daily oral prednisone vs. Zytiga and prednisone alone in about 80 patients who have PSA progression while...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >